Sofinnova

Press

 

Portfolio News

Sep 17, 2020

Athira Pharma Announces Pricing of Initial Public Offering

Athira Pharma Announces Pricing of Initial Public Offering

Portfolio News

Sep 17, 2020

Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease

Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease

Portfolio News

Sep 16, 2020

Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19

Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19

Portfolio News

Sep 15, 2020

Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis

Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis

Portfolio News

Sep 14, 2020

Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation

Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation

Portfolio News

Sep 08, 2020

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency

Portfolio News

Aug 17, 2020

Sanofi to Acquire Principia Biopharma

Sanofi to Acquire Principia Biopharma

Portfolio News

Aug 12, 2020

Ascendis Pharma Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe

Ascendis Pharma Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe

Portfolio News

Aug 06, 2020

Aerovate Therapeutics Emerges With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy

Aerovate Therapeutics Emerges With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy

Portfolio News

Jul 30, 2020

Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Portfolio News

Jul 28, 2020

Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration

Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration

Portfolio News

Jul 27, 2020

Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA®

Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA®

Portfolio News

Jul 27, 2020

Checkmate Granted FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade

Checkmate Granted FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade

Portfolio News

Jul 27, 2020

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer

Portfolio News

Jul 23, 2020

Inozyme Pharma Announces Pricing of Initial Public Offering

Inozyme Pharma Announces Pricing of Initial Public Offering

Portfolio News

Jul 21, 2020

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering

Portfolio News

Jul 20, 2020

Amplyx Announces Positive Top-Line Data in Phase 2 Clinical Trial Of Novel Antifungal Fosmanogepix

Amplyx Announces Positive Top-Line Data in Phase 2 Clinical Trial Of Novel Antifungal Fosmanogepix

Portfolio News

Jul 20, 2020

Checkmate Pharmaceuticals Executes a Snappy 1-2 Biotech Gambit — Big Crossover Followed by an Instant IPO

Checkmate Pharmaceuticals Executes a Snappy 1-2 Biotech Gambit — Big Crossover Followed by an Instant IPO

Portfolio News

Jul 17, 2020

Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals

Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals

Portfolio News

Jul 16, 2020

Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis

Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis

Portfolio News

Jul 14, 2020

Natera Recognized as a 'Force for Change' by Leading Women Entrepreneurs (LWE)

Natera Recognized as a 'Force for Change' by Leading Women Entrepreneurs (LWE)

Portfolio News

Jul 08, 2020

VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

Portfolio News

Jul 07, 2020

NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors

NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors

Portfolio News

Jul 06, 2020

Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan

Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan

Portfolio News

Jul 06, 2020

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

Portfolio News

Jun 30, 2020

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

Portfolio News

Jun 29, 2020

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY

Portfolio News

Jun 26, 2020

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

Portfolio News

Jun 26, 2020

Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

Portfolio News

Jun 25, 2020

Akouos Announces Pricing of Initial Public Offering

Akouos Announces Pricing of Initial Public Offering

Portfolio News

Jun 23, 2020

Karuna Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia

Karuna Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia

Portfolio News

Jun 23, 2020

Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

Portfolio News

Jun 15, 2020

Vascepa® Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified & Post Hoc Subgroup Analyses

Vascepa® Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified & Post Hoc Subgroup Analyses

Portfolio News

Jun 12, 2020

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus

Portfolio News

Jun 10, 2020

Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

Portfolio News

Jun 04, 2020

Athira Pharma Closes $85 Million Series B Financing

Athira Pharma Closes $85 Million Series B Financing

Portfolio News

May 14, 2020

Vascepa® Shows Significant Reduction in Coronary Revascularization in Prespecified Tertiary Endpoint Analyses

Vascepa® Shows Significant Reduction in Coronary Revascularization in Prespecified Tertiary Endpoint Analyses

Portfolio News

May 14, 2020

Inozyme Pharma & GACI Global Initiate Patient Study to Improve Understanding of the Impact of Disease in Patients with ENPP1 Deficiency & ABCC6 Deficiency

Inozyme Pharma & GACI Global Initiate Patient Study to Improve Understanding of the Impact of Disease in Patients with ENPP1 Deficiency & ABCC6 Deficiency

Portfolio News

May 13, 2020

Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease

Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease

Portfolio News

May 13, 2020

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

Event

Apr 24, 2020

Maha Katabi to join Biotech by the Lake Investor Summit Panel: "Financing and Investing in Oncology Biotech"

Maha Katabi to join Biotech by the Lake Investor Summit Panel: "Financing and Investing in Oncology Biotech"

Portfolio News

Apr 22, 2020

AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus

AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus

Portfolio News

Apr 22, 2020

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

Portfolio News

Apr 19, 2020

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial

Portfolio News

Apr 16, 2020

Natera Prices $250 Million Convertible Senior Notes Due 2027

Natera Prices $250 Million Convertible Senior Notes Due 2027

Portfolio News

Apr 15, 2020

Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering

Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering

Portfolio News

Apr 15, 2020

Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

Portfolio News

Apr 01, 2020

Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

Sofinnova News

Mar 31, 2020

Sofinnova Investments Strengthens Executive Team with the Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD

Sofinnova Investments Strengthens Executive Team with the Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD

Sofinnova News

Mar 17, 2020

Sofinnova Investments Announces the Addition of Jonathan Leff, M.D. as Executive Partner

Sofinnova Investments Announces the Addition of Jonathan Leff, M.D. as Executive Partner

Portfolio News

Mar 03, 2020

Akouos Closes $105 Million Series B Financing

Akouos Closes $105 Million Series B Financing

Portfolio News

Feb 26, 2020

Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

Portfolio News

Feb 14, 2020

Promedior Announces Completion of Acquisition by Roche

Promedior Announces Completion of Acquisition by Roche

Event

Feb 07, 2020

Maha Katabi to Present at the "Meet with Series" hosted by Johnson & Johnson Innovation, JLABS

Maha Katabi to Present at the "Meet with Series" hosted by Johnson & Johnson Innovation, JLABS

Event

Feb 05, 2020

Jason Pitts to Moderate Bio CEO and & Investor Conference Panel: "Neuroscience at the Crossroads: Late Stage Brain Disorder Pipelines and Unmet Needs"

Jason Pitts to Moderate Bio CEO and & Investor Conference Panel: "Neuroscience at the Crossroads: Late Stage Brain Disorder Pipelines and Unmet Needs"

Event

Jan 20, 2020

Jim Healy to join SuperReturn 2020 Panel: "Keeping Things Private or Going Public - Considering the Exit"

Jim Healy to join SuperReturn 2020 Panel: "Keeping Things Private or Going Public - Considering the Exit"

Portfolio News

Jan 15, 2020

Astellas Completes Acquisition of Audentes Therapeutics

Astellas Completes Acquisition of Audentes Therapeutics

Portfolio News

Jan 13, 2020

Chiasma Announces FDA Acceptance Of MYCAPSSA® New Drug Application Resubmission

Chiasma Announces FDA Acceptance Of MYCAPSSA® New Drug Application Resubmission

Portfolio News

Jan 08, 2020

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH

Event

Dec 17, 2019

Maha Katabi to join Biotech Showcase 2020 Panel "Rare and Orphan Diseases: The Value Proposition of New Modalities vs Established Ones"

Maha Katabi to join Biotech Showcase 2020 Panel "Rare and Orphan Diseases: The Value Proposition of New Modalities vs Established Ones"

Portfolio News

Dec 02, 2019

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutic

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutic

Portfolio News

Nov 20, 2019

Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

Portfolio News

Nov 18, 2019

Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

Portfolio News

Nov 18, 2019

Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

Portfolio News

Oct 25, 2019

Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

Portfolio News

Oct 21, 2019

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

Portfolio News

Oct 03, 2019

Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases

Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases

Event

Oct 01, 2019

Jim Healy to join BIO Investor Forum Panel "Market Outlook—Taking the Temperature of the IPO Market in an Era of Large Pharma M&A"

Jim Healy to join BIO Investor Forum Panel "Market Outlook—Taking the Temperature of the IPO Market in an Era of Large Pharma M&A"

Portfolio News

Sep 26, 2019

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

Portfolio News

Sep 23, 2019

Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back

Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back

Portfolio News

Sep 12, 2019

Akouos Discloses Lead Program, AK-OTOF, a Potential Gene Therapy for Sensorineural Hearing Loss

Akouos Discloses Lead Program, AK-OTOF, a Potential Gene Therapy for Sensorineural Hearing Loss

Portfolio News

Sep 09, 2019

Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

Portfolio News

Aug 07, 2019

ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

Portfolio News

Aug 05, 2019

Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema

Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema

Portfolio News

Aug 05, 2019

Natera Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies

Natera Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies

Portfolio News

Jul 23, 2019

Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa®

Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa®

Portfolio News

Jul 15, 2019

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria

Portfolio News

Jul 08, 2019

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1

Portfolio News

Jun 27, 2019

Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering

Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering

Sofinnova News

May 31, 2019

Swinging for the Fences: The Dichotomy in Rare Disease Investment and Development

Swinging for the Fences: The Dichotomy in Rare Disease Investment and Development

Portfolio News

May 14, 2019

CinCor Pharma Closes $50 Million Series A

CinCor Pharma Closes $50 Million Series A

Sofinnova News

Apr 22, 2019

Sofinnova Investments Announces the Addition of Industry Veteran Maha Katabi, PhD. as a Partner

Sofinnova Investments Announces the Addition of Industry Veteran Maha Katabi, PhD. as a Partner

Portfolio News

Apr 10, 2019

Inozyme Pharma Raises $67 Million in Series A2 Financing

Inozyme Pharma Raises $67 Million in Series A2 Financing

Portfolio News

Mar 28, 2019

Amarin shares new updates to the American Diabetes Association 2019 Standards of Medical Care in Diabetes

Amarin shares new updates to the American Diabetes Association 2019 Standards of Medical Care in Diabetes

Portfolio News

Mar 19, 2019

Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation

Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation

Portfolio News

Mar 04, 2019

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint

Portfolio News

Feb 25, 2019

Spark Therapeutics Enters into Definitive Merger Agreement with Roche

Spark Therapeutics Enters into Definitive Merger Agreement with Roche

Event

Feb 04, 2019

Jim Healy to join Bio CEO & Investor Panel "Are Record Levels of IPOs Still Disrupting M&A Deals?"

Jim Healy to join Bio CEO & Investor Panel "Are Record Levels of IPOs Still Disrupting M&A Deals?"

Portfolio News

Jan 31, 2019

Kiniksa Pharmaceuticals Announces Pricing of Public Offering

Kiniksa Pharmaceuticals Announces Pricing of Public Offering

Sofinnova News

Jan 25, 2019

A Top VC At a $2B Fund That Invests in Risky Biotechs Reveals How He Finds His Best Investments

A Top VC At a $2B Fund That Invests in Risky Biotechs Reveals How He Finds His Best Investments

Event

Dec 13, 2018

Mike Powell joins AACR Panel "Entrepreneurship in Translational Research"

Mike Powell joins AACR Panel "Entrepreneurship in Translational Research"

Event

Dec 12, 2018

Jim Healy to join Biotech Showcase Panel "Rare and Orphan Diseases"

Jim Healy to join Biotech Showcase Panel "Rare and Orphan Diseases"

Event

Dec 12, 2018

Jim Healy to join East | West CEO Panel "VC Perspectives: Currant Financing Trends in Biotech"

Jim Healy to join East | West CEO Panel "VC Perspectives: Currant Financing Trends in Biotech"

Portfolio News

Dec 06, 2018

XyloCor Therapeutics Raises $17 Million in Series A

XyloCor Therapeutics Raises $17 Million in Series A

Portfolio News

Nov 27, 2018

BioClin Therapeutics Announces Name Change to Rainier Therapeutics

BioClin Therapeutics Announces Name Change to Rainier Therapeutics

Portfolio News

Nov 13, 2018

NextCure Completes a $93M Series B Financing

NextCure Completes a $93M Series B Financing

Portfolio News

Nov 07, 2018

InCarda Completes $42M Oversubscribed Series B Financing

InCarda Completes $42M Oversubscribed Series B Financing

Portfolio News

Nov 05, 2018

NextCure and Lilly Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines

NextCure and Lilly Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines

Portfolio News

Nov 02, 2018

U.S. FDA Approves Coherus Biosciences' UDENYCA™

U.S. FDA Approves Coherus Biosciences' UDENYCA™

Sofinnova News

Oct 29, 2018

Sarah Bhagat Named as One of the "Nine VCs Who Matter, but You Never Read About"

Sarah Bhagat Named as One of the "Nine VCs Who Matter, but You Never Read About"

Sofinnova News

Oct 16, 2018

Mike Powell and Jason Pitts Featured in EndPoints Guest Column "The Real Cost of Drug Development"

Mike Powell and Jason Pitts Featured in EndPoints Guest Column "The Real Cost of Drug Development"

Portfolio News

Oct 03, 2018

ObsEva Reports Additional Positive Phase 3 Results IMPLANT 2 Trial Following IVF

ObsEva Reports Additional Positive Phase 3 Results IMPLANT 2 Trial Following IVF

Portfolio News

Sep 28, 2018

ObsEva’s Final Results of Phase 2b EDELWEISS Trial Shows Sustained Efficacy and Safety

ObsEva’s Final Results of Phase 2b EDELWEISS Trial Shows Sustained Efficacy and Safety

Portfolio News

Sep 26, 2018

Entasis Therapeutics Announces Pricing of Initial Public Offering

Entasis Therapeutics Announces Pricing of Initial Public Offering

Portfolio News

Sep 25, 2018

Coherus Biosciences Receives European Commission Approval for Udenyca™

Coherus Biosciences Receives European Commission Approval for Udenyca™

Portfolio News

Sep 24, 2018

Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® Capsules Met Primary Endpoint

Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® Capsules Met Primary Endpoint

Portfolio News

Sep 20, 2018

Y-mAbs Therapeutics Announces Pricing of Initial Public Offering

Y-mAbs Therapeutics Announces Pricing of Initial Public Offering

Portfolio News

Sep 19, 2018

Galera Therapeutics Raises $150M

Galera Therapeutics Raises $150M

Portfolio News

Sep 18, 2018

BioClin Therapeutics Announces New Leadership

BioClin Therapeutics Announces New Leadership

Portfolio News

Sep 13, 2018

Principia Biopharma Announces Pricing of Initial Public Offering

Principia Biopharma Announces Pricing of Initial Public Offering

Portfolio News

Aug 16, 2018

A women’s health startup tried to drum up interest for a much-needed drug. Many men didn’t get it.

A women’s health startup tried to drum up interest for a much-needed drug. Many men didn’t get it.

Portfolio News

Aug 07, 2018

Akouos Raises $50M Series A Financing

Akouos Raises $50M Series A Financing

Portfolio News

May 24, 2018

Iterum Announces the Pricing of Initial Public Offering

Iterum Announces the Pricing of Initial Public Offering

Portfolio News

May 23, 2018

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering

Portfolio News

May 14, 2018

Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282

Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282

Portfolio News

May 07, 2018

BioClin Therapeutics, Inc., Completes $50M Series B Financing with Addition of New Investors

BioClin Therapeutics, Inc., Completes $50M Series B Financing with Addition of New Investors

Portfolio News

Mar 28, 2018

Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study

Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study

Event

Jan 30, 2018

Alan Colowick to Speak at JLABS

Alan Colowick to Speak at JLABS

Portfolio News

Jan 22, 2018

Medeor Therapeutics Awarded $18.8M From the California Institute for Regenerative Medicine

Medeor Therapeutics Awarded $18.8M From the California Institute for Regenerative Medicine

Portfolio News

Jan 04, 2018

Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO

Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO

Portfolio News

Jan 03, 2018

Ascendis Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone

Ascendis Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone

Portfolio News

Dec 19, 2017

Spark Therapeutics Announces FDA approval of LUXTURNA™

Spark Therapeutics Announces FDA approval of LUXTURNA™

Portfolio News

Dec 18, 2017

Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa®

Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa®

Portfolio News

Dec 15, 2017

Aclaris Therapeutics Receives FDA Approval for the Treatment of Raised Seborrheic Keratoses

Aclaris Therapeutics Receives FDA Approval for the Treatment of Raised Seborrheic Keratoses

Portfolio News

Dec 13, 2017

Pionyr Immunotherapeutics Completes $62M Series B Financing

Pionyr Immunotherapeutics Completes $62M Series B Financing

Portfolio News

Nov 29, 2017

Y-mAbs Announces Closing of $30M Extension of Private Equity Placement

Y-mAbs Announces Closing of $30M Extension of Private Equity Placement

Portfolio News

Nov 28, 2017

Medeor Therapeutics Raises $57M In Series B Financing

Medeor Therapeutics Raises $57M In Series B Financing

Portfolio News

Nov 14, 2017

Apellis Announces the Pricing of Initial Public Offering

Apellis Announces the Pricing of Initial Public Offering

Portfolio News

Nov 07, 2017

ObsEva Announces Completion of Patient Recruitment for the Treatment of Endometriosis

ObsEva Announces Completion of Patient Recruitment for the Treatment of Endometriosis

Sofinnova News

Oct 24, 2017

Sofinnova Steps Up

Sofinnova Steps Up

Portfolio News

Sep 27, 2017

NuCana PLC Announces Pricing of Initial Public Offering

NuCana PLC Announces Pricing of Initial Public Offering

Portfolio News

Sep 05, 2017

Entasis Announces $31.9M Extension of Series B Financing

Entasis Announces $31.9M Extension of Series B Financing

Portfolio News

Aug 10, 2017

Apellis Pharmaceuticals Announces $60M Series E Financing

Apellis Pharmaceuticals Announces $60M Series E Financing

Portfolio News

Aug 02, 2017

Amplyx Pharmaceuticals Raises $67M in Series C Financing

Amplyx Pharmaceuticals Raises $67M in Series C Financing

Portfolio News

Jun 15, 2017

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals

Event

Jun 09, 2017

Jim Healy to Speak at BIO on Market & Political Pressures

Jim Healy to Speak at BIO on Market & Political Pressures

Event

Jun 07, 2017

Mike Powell to be a Judge at BIO's Start-Up Stadium

Mike Powell to be a Judge at BIO's Start-Up Stadium

Sofinnova News

May 30, 2017

Sofinnova Announces the Addition of Industry Leader Alan Colowick, MD, MPH to its Partnership

Sofinnova Announces the Addition of Industry Leader Alan Colowick, MD, MPH to its Partnership

Event

Apr 11, 2017

Jim Healy to Speak at Cancer Advance Boston

Jim Healy to Speak at Cancer Advance Boston

Portfolio News

Mar 28, 2017

Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy

Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy

Event

Feb 06, 2017

Charlotte Shropshire to Speak at SuperReturn US West

Charlotte Shropshire to Speak at SuperReturn US West

Sofinnova News

Oct 17, 2016

Sofinnova Raises $650M Biotech-focused Venture Fund

Sofinnova Raises $650M Biotech-focused Venture Fund

Sofinnova News

Apr 11, 2016

12 VCs Who Matter, But You Never Read About

12 VCs Who Matter, But You Never Read About

Sofinnova News

Jan 12, 2016

Despite 'choppy' markets, fundamentals strong as health care world heads to JPM

Despite 'choppy' markets, fundamentals strong as health care world heads to JPM